Cycuria Therapeutics (Cycuria), a preclinical stage biotechnology company pioneering breakthrough protein-based targeted therapies ...

Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results. See why I rate IMUX ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

FDA-approved TNKase is available at OhioHealth Shelby Hospital for the treatment of acute ischemic stroke for adults.

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest ...